Background. Multidrug resistance (MDR) among pathogens, defined as resistance to three or more antimicrobial classes, is an increasingly prevalent event in the management of the infected hospitalized patient. While Enterobacteriaceae with enzymemediated resistance and Acinetobacter spp. may satisfy this criterion, P. aeruginosa (PSA) is a nosocomial pathogen that has a history of intrinsic or developed resistance to many commonly utilized agents. As such, this organism is frequently considered among the most difficult-to-treat MDR pathogens.
Methods. Non duplicate, non urine PSA (n = 973) from 42 US hospitals collected between June 2013 -March 2014 were phenotypically assessed against a variety of antimicrobials using standard CLSI broth microdilution methods. MDR organisms were selected if they displayed resistance to 3 or more of the following classes as represented by resistance to: ciprofloxacin (CIP, MIC ≥4 mg/L), imipenem (IMP, MIC ≥8 mg/L), ceftazidime (CAZ, MIC ≥32 mg/L), piperacillin/tazobactam (TZP, MIC ≥128 mg/L), and tobramycin (TOB, MIC ≥16 mg/L). For comparative purposes, the breakpoint of 8mg/L was used for ceftolozane/tazobactam (TOL/TAZ).
Results. 12% (n = 115) of PSA were determined to be MDR. Rank order susceptibility (MIC 90 , mg/L) was as follows: colistin 97% (1), TOL/TAZ 86% (32), TOB 51% (128), aztreonam 19% (128), IMP 17% (32), meropenem 16% (32), CIP 13% (32), CAZ 11% (128), cefepime 10% (128), and TZP 9% (512). While the MIC 90 was 32 for TOL/TAZ, 30% of these organisms had MICs ≤1 mg/L, 24% = 2 mg/L, 26% = 4 mg/L, and 6% = 8 mg/L Conclusion. In this recent collection of PSA obtained from acute-care hospitals across the US, 12% were MDR based on conventional therapeutic benchmarks. While colistin displayed the highest susceptibility and lowest MIC 90 value, concerns related to its pharmacodynamic optimization and toxicity make alternative therapies a necessity. TOL/TAZ appears to retain potency against a majority (86%) of these MDR PSA where as other agents tested had %S of 9 -51%. Additional clinical data are needed to delineate the potential effectiveness of TOL/TAZ in the setting of infection with MDR PSA. 
